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We describe posterior reversible encephalopathy syndrome (PRES) in a woman with mul-
tiple sclerosis treated with Gilenya® (Fingolimod). The first symptoms appeared after
21 months of fingolimod treatment. She experienced headache, altered mental status, cog-
nitive deficits, seizures, and visual disturbances. Not at any time during the course of the
disease could any signs of infection or rheumatic disorder be detected.Test for anti-neuronal
antibodies was also negative. Her blood pressure was normal. MRI showed widespread
cortical and subcortical changes with some mass-effect in the temporo-occipital-parietal
lobes in the left hemisphere. Contrast enhancement was seen in the leptomeninges and,
in addition, there were no areas with restricted diffusion and no signs of hemorrhage. Her
condition deteriorated until fingolimod was discontinued. Slowly her condition improved
and after 8 months, the only symptoms that remained were two small, non-corresponding,
right inferior scotomas.We believe that all symptoms, the clinical course, and the MRI find-
ings in this case can all be explained by considering PRES, a probably rare, but serious,
side effect of fingolimod treatment.
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CASE PRESENTATION
In September 2005, a 38-year-old woman suddenly experienced
diplopia. Examinations in her homeland revealed MRI lesions typ-
ical for multiple sclerosis (MS). Analysis of the cerebrospinal fluid
showed oligoclonal IgG bands and a high IgG index, but no pleo-
cytosis. However, no treatment was initiated at that time. She then
had her second relapse in July 2006 with numbness in both legs.
All these symptoms disappeared in 5 weeks. Betaseron® (Inter-
feron beta-1b) was initiated in January 2007. In July 2007, she
had moved to Sweden and was examined for the first time in our
hospital. At that time, she herself did not experience any clinical
symptoms, but she had signs on the neurological examination. All
tendon reflexes were slightly exaggerated on the right side of the
body, the sense of vibration was slightly decreased on the right
foot and slight gaze-dependent nystagmus was seen. An MRI scan
in August 2007 showed multiple lesions typical for MS of both
the brain (20 lesions) and spinal cord (10 lesions). She continued
her interferon beta-1b treatment. A new MRI scan in June 2008
did not show any new lesions. In January 2009, she experienced
numbness in her left arm and MRI showed a new lesion in the
thalamus. Due to mildly elevated liver transaminase levels and the
new relapse, interferon beta-1b treatment was discontinued and
Copaxone® (Glatiramer acetate) was initiated. A new MRI scan
in November 2010 displayed five new lesions and one of them
showed contrast enhancement, but she had not experienced any
new neurological symptoms. Since she was afraid of progressive
multifocal leukoencephalopathy (PML), Tysabri® (Natalizumab)
was not initiated (see more below). Instead, she continued her
glatiramer acetate treatment. A new MRI in May 2011 showed no
new lesions. Neurological examination in December 2011 showed
lost sense of vibration in both feet and exaggerated reflexes in
both legs.
GILENYA® (FINGOLIMOD) THERAPY
Because of the worsening of symptoms, fingolimod at a dose of
0.5 mg once daily was initiated in December 2011. The first MRI
after the initiation of fingolimod was done in January 2012 and
showed two new lesions, but no contrast enhancement was seen.
An MRI in July 2012 showed no new lesions. In March 2013, the
sense of vibration had normalized, but reflexes were still exagger-
ated in both legs. In July 2013, MRI displayed no new lesions. On
September 6 2013, she experienced symptoms of a urinary tract
infection, and because of that she contacted her general practi-
tioner. She was then treated with Selexid® (Pivmecillinam) for
3 days and symptoms ameliorated. A family member had commu-
nicated with her on September 15 and reported that everything had
been completely normal. On September 17, she again came in con-
tact with her general practitioner. She had been found disoriented
outside her home. She was at that time fully awake, but she had
some mild speech difficulties and apraxia. She was immediately
sent in to the nearest hospital, and not to our hospital. At that hos-
pital, some kind of CNS infection was suspected. However, blood
samples did not show any abnormalities and she had no fever or
any other signs of an ongoing infection. Also, rheumatological
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markers for inflammation/vasculitis were negative. A first lumbar
puncture was not done until September 21, and a second on Octo-
ber 3. No abnormalities were seen in any of the CSF (cerebrospinal
fluid) analysis. No pleocytosis, no rise in lactic acid or albumine
levels could be seen. Glucose levels were also normal. Interleukin
6 and 10, beta-Amyloid, and Tau levels were also normal. PCR
was negative for Mycobacterium, Herpes simplex 1 and 2, Vari-
cella zoster, enteroviruses, and JC-virus. No Borrelia or syphilis
antibodies were present. Fungus screening in the CSF was also
negative. In addition, anti-neuronal antibodies were negative in
both CSF and blood samples. MRI was, by unknown reasons, not
done until September 21 and was at that time described as not
changed from an earlier MRI done 2 months before (Figure 1). Her
condition had, however, deteriorated. She experienced a headache
with mild light sensitivity. She was somnolent and when she was
awake she had clear speech difficulties and was disoriented. EEG
was abnormal with generalized rhythmic slow activity of delta
frequency within the fronto-temporal regions, but no epileptic
discharges were seen. However, on September 25, she had a gener-
alized epileptic seizure. Her symptoms then continued to worsen.
She suffered from lethargy and had visual hallucinations. Delu-
sions were present and she was still disoriented. At this time and
also earlier, no hypertension was at hand, blood pressure had
always been around 120/80. Fingolimod had by unknown rea-
sons not been discontinued. A new EEG on September 26 showed
generalized slow activity over the whole left hemisphere, and in
the frontal region also episodic rhytmic delta activity with tripha-
sic like appearance was seen. Still, no epileptic discharges were
present. In spite of the lack of epileptic activity on the EEG, the
cause of all symptoms was thought to be primarily epileptic. Anti-
epileptic medication was initiated (Keppra®, Levetiracetam). On
October 2, our hospital was contacted for the first time and fin-
golimod was then without any delay discontinued since a rare side
effect was suspected. At that time, also a CT brain angiography was
done and, as expected, no signs of vasculitis were seen. Already a
week after discontinuation of fingolimod, the patient had slightly
improved. She was more awake and responded to questions, but
she had still speech difficulties and was confused. On October
11, a new MRI scan showed widespread cortical and subcortical
changes with some mass-effect in the temporo-occipital-parietal
lobes in the left hemisphere (Figure 2). Contrast enhancement
was also seen in the leptomeninges. There were no areas with
restricted diffusion and no signs of hemorrhage. Retrospectively,
subtle cortical edema could now be seen in the same areas in the
MRI scan from September. In addition, hyperperfusion could also
be seen in the same areas. A new EEG was done in October 18, but
no changes were seen compared with the registration on Octo-
ber 2. On October 23, the patient was moved to another hospital
for rehabilitation. At that time, she had still right homonymous
hemianopia. She had also still some speech difficulties and cog-
nitive deficits, but now she was fully oriented and had no visual
hallucinations. In November, acute intermittent porphyria was
also ruled out as a possible cause of her present condition. She
continued to improve and on January 27 2014, she could speak
without problems and the visual fields were nearly normal, only a
right inferior quadrantanopia remained. A visual examination on
April 15 showed only two small, non-corresponding, right infe-
rior scotomas, which do not obstruct her ability to drive a car. She
started to work halftime in May, and fulltime in June. An MRI on
May 15 showed unchanged neuroinflammatory lesion load and
superficial residual cortical lesions in parts of the occipital lobe.
When the clinical course and the imaging findings were analyzed
at our hospital, we found them highly consistent with posterior
reversible encephalopathy syndrome (PRES).
BACKGROUND
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME
Posterior reversible encephalopathy syndrome in general is
a relatively rare clinico-radiological entity first described in
1996 (1). Clinically, it is characterized by a subacute onset of
FIGURE 1 | MRI of the brain performed with FLAIR sequences on four
different scanners. (A) Before PRES in July 2013 (3D FLAIR 1,5T). (B) First
MRI on day 4 during PRES with subtle cortical edema (arrows; 2D FLAIR
1,5T). (C) Second MRI on day 24 during PRES with cortical and subcortical
vasogenic edema (arrows; 2D FLAIR 3T). (D) Follow-up MRI May 2014 with
small superficial residual changes (arrow) in part of the cortex (3D FLAIR 3T).
Chronic neuroinflammatory lesions are seen in the thalami and periventricular
white matter.
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FIGURE 2 | MRI of the brain on day 24 of PRES. Images show axial T2 (A) and sagittal FLAIR (B) with cortical edema and T1 with contrast enhancement
(D,E) of the leptomeninges. Right column images show DWI (C) and ADC (F) with vasogenic edema, but without areas with restricted diffusion.
headache, altered mental status, seizures, visual disturbances, and
occasionally other focal neurological signs (2, 3). Radiologically,
there are signs of vasogenic edema bilaterally in the white matter of
the parieto-occipital lobes, but changes can also be seen in frontal
and temporal lobes, brainstem, cerebellum, and in cortical as well
as deep gray matter (3–5). It is most often associated with other
medical conditions such as, for example, hypertensive crisis, renal
disorders, and eclampsia. However, different medications such as
immunosuppressive, chemotherapeutic, and cytotoxic agents are
also associated with PRES (2, 3). The underlying pathophysiology
is still unknown, but there are many theories. A consistent feature
in PRES seems to be dysfunction of the cerebral autoregulation
and impaired cerebrovascular blood–brain barrier (6). Cerebral
autoregulation is achieved by vasoconstriction or vasodilatation
of resistance arterioles, resulting in a constant blood flow to the
brain. In the case of significant hypertension, a rapid rise in blood
pressure that will overcome the capacity of the normal autoregula-
tion could produce vasodilatation, with a resulting hyperperfusion
and/or regional vasoconstriction of the brains arteries. This hyper-
perfusion could then cause endothelial dysfunction, resulting in an
extravasation of proteins and fluid, i.e., causing a vasogenic edema.
Arteries in the posterior regions of the brain seem to be especially
vulnerable, probably due to a relative lack of sympathetic innerva-
tion in these vessels (7). However, there could also be a direct toxic
effect on the vascular endothelium followed by a breakdown of the
blood–brain barrier and a dysfunction of the vascular autoregu-
lation (3, 6, 8). That could be the case, for example, in eclampsia,
sepsis, and in PRES associated with certain medications, especially
immunomodulating treatments. Probably, a damaged endothe-
lium could then per se contribute to a high blood pressure. Thus,
high blood pressure should not be mandatory in PRES and there
are indeed normotensive cases (9–11). The fact that a high per-
centage of patients with PRES have a history of autoimmune
disorders supports the idea that affected endothelium plays a role
in the pathophysiology of PRES (3, 12). The differential diagnosis
of PRES includes various acute neurological conditions such as
stroke, cerebral venous thrombosis, encephalitis, and demyelinat-
ing disorders (4, 6). PRES is best treated by a prompt reduction
of blood pressure, anti-epileptic therapy, and/or withdrawal of the
causing agent (4, 6).
GILENYA® (FINGOLIMOD)
On September 22 2010, fingolimod became the first oral
disease-modifying drug approved by the US Food and Drug
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Administration (FDA) to significantly reduce relapses and delay
disability progression in patients with relapsing forms of MS. MS
patients taking 0.5 mg fingolimod have 54% lower risk of relapses
than those taking placebo over 2 years (13). Another study showed
that MS patients taking fingolimod had a 52% lower risk of having
a relapse than patients taking Avonex® (Interferon beta-1a) over
1 year (14). On March 17 2011, the European Medicines Agency
(EMA) approved the drug for use in the European Union. As of
February 2014, 91,500 patients have been treated with fingolimod.
The most serious adverse effects are cardiac arrhythmias and mac-
ular edema. Patients with cardio-vascular risk factors are therefore
mostly excluded and a follow-up ophthalmological examination is
needed. PRES is probably a rare adverse effect of fingolimod. How-
ever, already in a premarketing study (15) one case was reported,
but the dose in that case (5 mg) was higher than recommended for
use in MS (0,5 mg).
DISCUSSION
Here, we report, what is to our knowledge, the first occurrence of
PRES in an MS patient treated with the recommended daily dose
of 0.5 mg fingolimod. The number of fingolimod treated patients
with PRES is unknown. However, in a 6 months study compar-
ing fingolimod doses of 1.25 or 5 mg with placebo, one case of
PRES was described in the 5 mg group already after 10 weeks of
treatment when headache, cortical blindness, ophthalmoplegia,
dysarthria, and ataxia developed (15). In contrast to most PRES
cases, this patient had no hypertension or renal disorder. MRI fea-
tures began to improve already 72 h after the discontinuation of
fingolimod. However, a residual right homonymous hemianopia
corresponding to a left occipital hyperintensity and a mild ataxia
remained and did not change after 15 months follow-up (15).
Thus, in parallel with that case of fingolimod associated PRES, our
patient also had clinical symptoms typical for PRES with visual
disturbance, disorientation, and epileptic seizures, but without
any hypertension or renal failure. In fact, PRES with no associated
hypertension has been described previously (9–11). In our case,
it could be speculated that fingolimod had a direct toxic effect on
the endothelium. A direct effect of fingolimod on the endothe-
lium has indeed been described. Fingolimod can cause an arterial
vasodilation and stimulate NO production (16). Fingolimod has
also been shown to modulate the integrity of the endothelium,
especially influencing the vascular permeability (17, 18). More-
over, fingolimod could also influence endothelial healing after
mechanic injury and impaired angiogenesis (19). The possibly
strong effect of fingolimod on arteries was further emphasized in
an MS patient with critical vasospasm of the left arm within 7 days
after having started treatment with fingolimod (20). In parallel
with fingolimod, PRES has also been described in one MS patient
treated with natalizumab (21). Natalizumab is a monoclonal anti-
body and a highly effective treatment for MS. Natalizumab reduces
the mean annualized relapse rate over 2 years by 68% compared to
placebo and 55% compared to interferon beta-1a (22, 23). As of
June 2014, 129,100 patients have been treated with natalizumab.
The natalizumab treated patient with PRES had, however, con-
comitantly an urosepsis and also a very high systolic blood pressure
at presentation. Both these conditions can per se cause PRES, thus
there are other possible reasons in that case (21). In our case, the
patient only had a mild urethritis with no increase in white blood
cell count and CRP. However, a urinary tract infection could not be
completely excluded as a contributing factor for PRES in our case.
The clinical presentation of PRES is often atypical, which makes
MRI crucial for the diagnosis. In our case, signs of cortical edema
could be seen already in the first MRI done 4 days after the ini-
tial symptoms but, unfortunately, it was not recognized. This fact
emphasizes the importance of an early diagnosis with MRI. The
MRI picture in our case was in many ways typical for PRES, with
the exception of an asymmetrical presentation. A unilateral MRI
appearance has, however, been described before and is estimated to
occur in <5% of patients (24, 25). Also, in the PRES case described
after 5 mg fingolimod, an asymmetrical MRI appearance was at
hand (15).
CONCLUDING REMARKS
Obviously, the new era of highly effective therapies for inflamma-
tory and autoimmune diseases carries risks of probably rare, but
serious, side effects. If diagnosis and treatment are delayed, the
result could be permanent damage to affected areas of the brain.
In parallel with natalizumab, serious side effects emerging in the
postmarketing phase have been shown for fingolimod. PML has
been shown to be associated with natalizumab (26, 27). PML is a
serious demyelinating disease of the central nervous system caused
by the human JC polyomavirus (28). As of September 2014, the
number of PML cases associated with natalizumab is 492 (Biogen
Idec, data on file). Accordingly, it is very important to know about
PRES as a possible side effect of fingolimod in order to quickly
recognize the condition and discontinue the medication. It is also
important to know about the prevalence, but according to Novartis
the only information accessible is that the number of PRES cases
reported in the postmarketing phase has not increased over time.
However, the exact number of PRES cases reported to Novartis is
kept confidential. Both PRES and PML (29) are very important to
discover in an early phase to minimize residual handicap.
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